Last reviewed · How we verify
TECHNETIUM MERTIATIDE
TECHNETIUM MERTIATIDE is a drug. It is currently FDA-approved (first approved 1990).
Technetium mertiatide is a radiopharmaceutical used in medical imaging studies, including those for Uric Acid Nephrolithiasis, Cancer, Drug Toxicity, and Kidney Failure. It is not a standalone treatment, but rather an intervention used in conjunction with other agents, such as 123I-BMIPP and 99mTc-MAG3, in clinical trials.
At a glance
| Generic name | TECHNETIUM MERTIATIDE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
Common side effects
Key clinical trials
- Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN) (NA)
- Tc-99m Renography and Cisplatin-induced Nephrotoxicity
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TECHNETIUM MERTIATIDE CI brief — competitive landscape report
- TECHNETIUM MERTIATIDE updates RSS · CI watch RSS
Frequently asked questions about TECHNETIUM MERTIATIDE
What is TECHNETIUM MERTIATIDE?
When was TECHNETIUM MERTIATIDE approved?
What development phase is TECHNETIUM MERTIATIDE in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing